Education
About Us
Working with TipRanks
Follow Us
Ardelyx Inc (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
$7.26
-$0.17(-3.14%)
At close: 4:00 PM EST
$7.26
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.21 - $8.40
Previous CloseN/A
Volume1.36M
Average Volume (3M)5.28M
Market Cap
$1.76B
Enterprise Value$1.83B
Total Cash (Recent Filing)$242.71M
Total Debt (Recent Filing)$207.61M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Feb 19, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding242,974,300
10 Day Avg. Volume3,030,976
30 Day Avg. Volume5,280,639
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)6.88
Price to Sales (P/S)3.57
P/FCF Ratio-26.03
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit5.18
Enterprise Value/Ebitda-64.56
Forecast
1Y Price Target
$14.86Price Target Upside104.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.17
Revenue Forecast (FY)$537.15M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentA Phase 3 study to evaluate Ibsrela in chronic idiopathic constipation broadens potential labeled uses and expands the drug's addressable patient population.
Commercial Execution And Financial RunwayExpanded commercial and field teams together with a solid cash position enable deeper physician outreach and sustained investment in marketing and pipeline programs to support sales growth.
Differentiated Mechanism And Unmet NeedIbsrela's mechanism of action differs from current secretagogue treatments, offering an option for patients inadequately managed on existing therapies and supporting physician adoption.
Bears Say
Clinical, Regulatory And Legal Execution RiskClinical and regulatory uncertainties around potential label expansions, along with legal questions that could affect patent clarity, create execution risks that could delay launches or weaken competitive positioning.
Xphozah Coverage And AccessLoss of Medicare Part D coverage for Xphozah has reduced patient access and created a more challenging commercial environment, constraining the product's recovery prospects.
Xphozah Sales MomentumGuidance indicating only modest revenue trends for Xphozah suggests limited acceleration in sales and dampened upside for the company.
Ardelyx News
ARDX FAQ
What was Ardelyx Inc’s price range in the past 12 months?
Ardelyx Inc lowest stock price was $3.21 and its highest was $8.40 in the past 12 months.
What is Ardelyx Inc’s market cap?
Ardelyx Inc’s market cap is $1.76B.
When is Ardelyx Inc’s upcoming earnings report date?
Ardelyx Inc’s upcoming earnings report date is Feb 19, 2026 which is in 5 days.
How were Ardelyx Inc’s earnings last quarter?
Ardelyx Inc released its earnings results on Oct 30, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.058.
Is Ardelyx Inc overvalued?
According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued.
Does Ardelyx Inc pay dividends?
Ardelyx Inc does not currently pay dividends.
What is Ardelyx Inc’s EPS estimate?
Ardelyx Inc’s EPS estimate is 0.01.
How many shares outstanding does Ardelyx Inc have?
Ardelyx Inc has 242,974,300 shares outstanding.
What happened to Ardelyx Inc’s price movement after its last earnings report?
Ardelyx Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went up 20.958%.
Which hedge fund is a major shareholder of Ardelyx Inc?
Currently, no hedge funds are holding shares in ARDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.86 (104.68% Upside)
$14.86 (104.68% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 58.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $800.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.52%
12-Months-Change
Fundamentals
Return on Equity
-36.18%
Trailing 12-Months
Asset Growth
32.16%
Trailing 12-Months
Company Description
Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Ardelyx's strong financial performance, driven by significant growth in IBSRELA and XPHOZAH revenue. The introduction of a new compound, ARDX-10531, marks a positive step in pipeline development. However, challenges remain, particularly in achieving XPHOZAH's long-term revenue goals amidst market disruptions.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$14.86
▲(104.68% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.68% Insiders
23.40% Mutual Funds
1.49% Other Institutional Investors
57.91% Public Companies and
Individual Investors